Dr Eng Soo Yap helps us understand more about the role of therapeutic plasma exchange (TPE) in treating iTTP and cTTP, and some of the challenges associated with the current treatment paradigm. He also shares insights on promising therapeutics such as TAK-755 that are currently under investigation. 

Dr Eng Soo Yap helps us understand more about the role of therapeutic plasma exchange (TPE) in treating iTTP and cTTP, and some of the challenges associated with the current treatment paradigm. He also shares insights on promising therapeutics such as TAK-755 that are currently under investigation.

Rare Disorders Digest is a Takeda podcast series designed to inform the audience about different rare diseases, and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.

Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.

Disclosures:

This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.

This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.

Intended for a general audience outside the US and UK.

Rare Disorders Digest is a Takeda podcast series designed to inform the audience about different rare diseases, and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.
Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.
Disclosures:
This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.
This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.
Intended for a general audience outside the US and UK.

Takeda Rare Disorders Digest

Rare Disorders Digest is a Takeda podcast series designed to inform the audience about Thrombotic Thrombocytopenic Purpura (TTP) and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.

Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.

Disclosures:

This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.

This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.

Intended for a general audience outside the US and UK.

Rare Disorders Digest is a Takeda podcast series designed to inform the audience about Thrombotic Thrombocytopenic Purpura (TTP) and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.
Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.
Disclosures:
This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.
This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.
Intended for a general audience outside the US and UK.

Takeda Rare Disorders Digest - Thrombotic Thrombocytopenic Purpura (TTP)

Rare Disorders Digest

Episode 3 – Treatment of TTP

We head to the clinic this week to hear about Prof. Joe Sasadeusz’s clinical experiences with treating CMV, and the common challenges faced when managing patients with CMV infections. Learn about considerations when selecting between prophylactic and preemptive therapy for patients with CMV infections.

We head to the clinic this week to hear about Prof. Joe Sasadeusz’s clinical experiences with treating CMV, and the common challenges faced when managing patients with CMV infections. Learn about considerations when selecting between prophylactic and preemptive therapy for patients with CMV infections.

Episode 3 – Clinical experience and challenges with treating post-transplant CMV infection

We chat with Prof. Joe Sasadeusz about current and upcoming approaches to diagnose and treat CMV infections. Prof. Sasadeusz also shares his thoughts on the strengths and limitations of current prophylactic and preemptive treatment strategies and gives us a glimpse into the future of CMV treatment.

We chat with Prof. Joe Sasadeusz about current and upcoming approaches to diagnose and treat CMV infections. Prof. Sasadeusz also shares his thoughts on the strengths and limitations of current prophylactic and preemptive treatment strategies and gives us a glimpse into the future of CMV treatment.

Episode 2 – Diagnosis and Treatment of Post-Transplant CMV infection

CMV is a common and yet permanent infection that poses risks to people with weakened immune systems. In this episode, Prof. Joe Sasadeusz sets the scene by giving an overview of these infections alongside patient advocate, Ms Lisa Foster.

CMV infections have serious consequences, especially those in high-risk groups, such as those with AIDS, and patients who are receiving immunosuppressants following a solid organ (SOT) or hematopoietic stem cell transplant (HSCT).

CMV is a common and yet permanent infection that poses risks to people with weakened immune systems. In this episode, Prof. Joe Sasadeusz sets the scene by giving an overview of these infections alongside patient advocate, Ms Lisa Foster.
CMV infections have serious consequences, especially those in high-risk groups, such as those with AIDS, and patients who are receiving immunosuppressants following a solid organ (SOT) or hematopoietic stem cell transplant (HSCT).

Episode 3 – Treatment of TTP

In 1 playlist(s)

Rare Disorders Digest

Social links

Follow podcast

Recent clips